 COA |
MSDS |
 HPLC |
NMR |
| CAS No: | 49671-76-3 |
| Molecular formula(MF) | C17H18N2 |
| Molecular Weight(MW): | 250.34 |
| Alias |
| In vitro | DMSO | 37 mg/mL (147.79 mM) |
|---|---|---|
| Ethanol | 2 mg/mL (7.98 mM) | |
| Water | <1 mg/mL | |
| In vivo |
| Description | ZLN005 is a potent and tissue-specific PGC-1α transcriptional activator. | |
|---|---|---|
| Targets |
|
|
| In vitro |
In L6 myotubes, ZLN005 increases expression of the PGC-1α gene and downstream genes by activation of AMP-activated protein kinase, and improves glucose uptake and fatty acid oxidation without obvious cytotoxicity. While ZLN005 does not has the same effects in rat primary hepatocytes, which suggests cell type–specificity. [1] |
|
| In vivo | ZLN005 (15 mg/kg, p.o.) produces antihyperglycemia and antihyperlipidemia effects and increases insulin sensitivity in db/db mice but not lean mice. [1] |